Evidence map›Paper›PMID 22355700›Full record

ArticleScientific reports2011

Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance.

Virginie Supervie, Meagan Barrett, James S Kahn, Godfrey Musuka, Themba Lebogang Moeti, Lesego Busang, Lesogo Busang, Sally Blower

Erratum issuedAbstract read
In one paragraph

Article in Scientific reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Methodological concerns regarding a PrEP model.The Lancet. Infectious diseases · 2017
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Virginie SupervieSemel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, California. USA.
Meagan Barrett
James S Kahn
Godfrey Musuka
Themba Lebogang Moeti
Lesego Busang
Lesogo Busang
Sally Blower

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
HIV, TB, HSV 2--EMERGENCE OF DRUG RESISTANCER01AI041935 · NIAID · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI BLOWER, SALLY MARGARET · 1998 to 2012
$6.6M
Mentoring HIV and Translational Scientists and Developing an EMR Based ResearchK24RR024369 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KAHN, JAMES S · 2007 to 2011
$553k
Designing optimal interventions to control HIV in Africa using data-based modelsR21AI086701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BLOWER, SALLY MARGARET · 2010 to 2011
$422k
NCRR NIH HHS K24 RR024369NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI041935NIAID NIH HHS R01 AI041935-12S1NIAID NIH HHS R21 AI086701
6 · The paper itself

Abstract

Clinical trials have recently demonstrated the effectiveness of Pre-Exposure Prophylaxis (PrEP) in preventing HIV infection. Consequently, PrEP may soon be used for epidemic control. We model the dynamic interactions that will occur between treatment programs and potential PrEP interventions in resource-constrained countries. We determine the consequences for HIV transmission and drug resistance. We use response hypersurface modeling to predict the effect of PrEP on decreasing transmission as a function of effectiveness, adherence and coverage. We predict PrEP will increase need for second-line therapies (SLT) for treatment-naïve individuals, but could significantly decrease need for SLT for treatment-experienced individuals. If the rollout of PrEP is carefully planned it could increase the sustainability of treatment programs. If not, need for SLT could increase and the sustainability of treatment programs could be compromised. Our results show the optimal strategy for rolling out PrEP in resource-constrained countries is to begin around the "worst" treatment programs.

Indexed as

Drug Resistance, ViralAdolescentAdultBotswanaFemaleHIV InfectionsHumansIncidenceMaleMiddle AgedModels, StatisticalMutationPrevalenceSensitivity and SpecificitySurface PropertiesUncertainty

Identifiers

PMID22355700
PMCPMC3240958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.